Valeant Racks Up FDA Letters Criticizing Its Promotional Materials
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says Valiant’s webpage for Zovirax overstates the efficacy of the herpes drug and makes unsubstantiated claims it is superior to Valtrex. It is the fifth letter the agency has sent the company in the past year.